Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creon36 for Pancreatic Malabsorption in Chronic Pancreatitis
NCT02849704Phase 2Completed
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Oct 2016
- Primary completion
- Nov 2017
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pancreatin in exocrine pancreatic insufficiency (EPI) (2 arms), sponsored by Children's Hospital of Philadelphia. Primary endpoints: Malabsorption Blood Test Mean HA AUC at 8 hours, Coefficient of Fat Absorption at 72 hours and 1 more. Started Oct 2016; status: completed.
02
Drugs
pancreatin
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT02849704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02849704.